[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"supplementary-motor-area\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:supplementary-motor-area":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100545541","the-efficacy-and-safety-of-precision-repetitive-transcranial-magnetic-stimulation-in-alleviating-motor-symptom-in-parkinsons-disease-100545541",false,"NCT06383247","The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease","A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)","Inclusion Criteria:\n\n1. Age ≥ 40 years old;\n2. Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\\[1\\];\n3. Have no history of drug adjustment within 4 weeks before treatment and the entire study period;\n4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;\n5. MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.\n\nExclusion Criteria:\n\n1. Previously head MRI\u002FCT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);\n2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);\n3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;\n4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.\n5. The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;\n6. Diagnosed with a neuropsychiatric disorder other than PD\n7. Have a history of drug abuse or drug use;\n8. Participants in any clinical trial within the previous 6 month;\n9. Pregnant\u002Flactating women or subjects (including men) who have a birth plan within 6 months;\n10. Other conditions deemed unsuitable for inclusion by the investigator.","ALL","40 Years",{"count":19,"type":20},290,"ESTIMATED","INTERVENTIONAL",[23],"NA","Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.",[26,27,28],"Parkinson Disease","Transcranial Magenetic Stimualtion","Supplementary Motor Area",[26,30,31],"transcranial magenetic stimualtion","supplementary motor area","RECRUITING","2025-06-14",{"date":35,"type":36},"2025-06-17","ACTUAL",{"date":38,"type":36},"2024-12-06",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"Anhui Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":24,"conditions":54,"keywords":55,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100560909","the-efficacy-of-repetitive-transcranial-magnetic-stimulation-in-parkinson39s-diseasea-randomized-double-blind-multicenter-placebo-controlled-trial-100560909","NCT06583278","The Efficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease：A Randomized, Double-blind, Multicenter, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Age ≥40 years old\n2. Meet Movement Disorder Society standards;\n3. Have no history of drug adjustment within 4 weeks before and during treatment;\n4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4\n5. MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.\n\nExclusion Criteria:\n\n1. Head MRI\u002FCT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);\n2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);\n3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;\n4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.\n5. The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;\n6. Diagnosed with a neuropsychiatric disorder other than PD\n7. Have a history of drug abuse or drug use;\n8. Participants in any clinical trial within the previous 6 month;\n9. Pregnant\u002Flactating women or subjects (including men) who have a birth plan within 6 months;\n10. Other conditions deemed unsuitable for inclusion by the investigator.",{"count":52,"type":20},312,[23],[26,27,28],[26,27,28],"NOT_YET_RECRUITING","2024-09-01",{"date":59,"type":36},"2024-09-04",{"date":61,"type":20},"2024-11-01",{"date":63,"type":20},"2027-06-30",{"name":42,"class":43},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":44},"100557813","an-open-label-study-on-the-clinical-efficacy-of-rtms-intervention-in-pd-100557813","NCT06542991","An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD",{"count":71,"type":20},20,[23],"To demonstrate that intervention targeting the supplementary motor area (SMA) using precise navigation positioning can effectively improve motor symptoms in patients with Parkinson's disease.",[75,26,28],"Transcranial Magnetic Stimulation",[75,26,77],"Supplementary motor area","2024-08-03",{"date":80,"type":36},"2024-08-07",{"date":57,"type":20},{"date":83,"type":20},"2025-03-31",{"name":42,"class":43}]